New York, NY -- (SBWIRE) -- 01/28/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Forest Oil Corporation (NYSE:FST), Penn West Petroleum Ltd (USA) (NYSE:PWE), Synta Pharmaceuticals Corp (NASDAQ:SNTA), ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC)
Forest Oil Corporation (NYSE:FST) showed a volume of 3.14 million shares by the end of last trade whereas the average volume of the stock remained 3.63 million shares. The stock opened the session at $3.45 but then moved to $3.31. At that price, the stock showed a negative performance of -4.34%. Forest Oil Corporation (Forest) is an independent oil and gas company engaged in the acquisition, exploration, development, and production of oil, natural gas, and natural gas liquids in North America. As of December 31, 2011, Forest's total estimated proved oil and gas reserves were approximately 1,904 billions of cubic feet equivalents.
Will FST Get Buyers Even After The Recent Rally? Find Out Here
Penn West Petroleum Ltd (USA) (NYSE:PWE) opened the session at $7.38 and closed the session at $7.28. The stock showed a negative performance of -1.22% in previous trading session. Traded with volume of 3.13 million shares in the prior session and the average volume of the stock remained 2.52 million shares. Penn West Petroleum Ltd. (Penn West), formerly Penn West Energy Trust, is a Canadian exploration and production company. Penn West is engaged in the business of acquiring, exploring, developing, exploiting and holding interests in petroleum and natural gas properties and related assets.
Has PWE Found The Bottom And Ready To Gain Momentum? Find Out Here
Synta Pharmaceuticals Corp (NASDAQ:SNTA) opened the session at $6.05 and closed the session at $5.45. The stock showed a negative performance of -10.50% in previous trading session. Traded with volume of 3.12 million shares in the prior session and the average volume of the stock remained 1.96 million shares. The beta of the stock remained 3.10. Synta Pharmaceuticals Corp. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases.
Why Should Investors Buy SNTA After the Recent Fall? Just Go Here and Find Out
ImmunoCellular Therapeutics Ltd (NYSEMKT:IMUC) the stock decreased -3.17% and finished the session at $1.22. Traded with volume of 3.10 million shares in the prior session and the average volume of the stock remained 5.17 million shares. The beta of the stock remained 2.64. ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies.
Will IMUC Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)